Exopharm
Exopharm uses extracellular vesicles (EVs) for the delivery of various types of active ingredient, including DNA, RNA, small molecules and proteins, to selected cell types and organs. Exopharm’s manufacturing technology, Exopharm uses its technologies in its own product pipeline as well for biopharma partner drug candidates.
Headquarters
Exopharm Limited
Level 17/31 Queen St
Melbourne
VIC 3000
Australia
Exopharm is a clinical-stage biopharmaceutical company that uses extracellular vesicles (EVs) to deliver a new class of transformative medicines. Its technologies provide advanced customisation of EVs to improve delivery of active ingredients, including DNA, RNA, small molecules and proteins, to selected cell types and organs. Exopharm’s manufacturing technology, LEAP, provides access to large quantities of high-purity EVs for research and clinical uses. Exopharm uses variations and combinations of these technologies to pursue its own product pipeline as well as to enable its biopharma partners to improve delivery of their drug candidates.
Exopharm was founded in 2013, and in 2016 it was listed on the Australian Stock Exchange (ASX:EX1).
Authors and Contacts
Article
